Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S K Dhesy-Thind

Showing results (1-10 of 4) with videos related to

Pageof 1
Sort By:
Current Oncology (Toronto, Ont.)|December 31, 2020
Code status communication training in postgraduate oncology programs: a needs assessmentO H Levine, S K Dhesy-Thind, M M McConnell, et al.
Breast Cancer Research and Treatment|June 20, 2018
Thyroid hormone receptor beta-1 expression in early breast cancer: a validation studyK J Jerzak, J G Cockburn, S K Dhesy-Thind, et al.
British Journal of Cancer|May 6, 2015
(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancerJ J You, K J Cline, C-S Gu, et al.
Breast Cancer Research and Treatment|October 14, 2017
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213V Bernstein, S L Ellard, S F Dent, et al.
Pageof 1

Showing results (1-10 of 4) with videos related to

Sort By:
Pageof 1
Current Oncology (Toronto, Ont.)|December 31, 2020
Code status communication training in postgraduate oncology programs: a needs assessmentO H Levine, S K Dhesy-Thind, M M McConnell, et al.
Breast Cancer Research and Treatment|June 20, 2018
Thyroid hormone receptor beta-1 expression in early breast cancer: a validation studyK J Jerzak, J G Cockburn, S K Dhesy-Thind, et al.
British Journal of Cancer|May 6, 2015
(18)F-fluorodeoxyglucose positron-emission tomography-computed tomography to diagnose recurrent cancerJ J You, K J Cline, C-S Gu, et al.
Breast Cancer Research and Treatment|October 14, 2017
A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213V Bernstein, S L Ellard, S F Dent, et al.
Pageof 1